The therapeutic utility of Фенспирид (Fenspiride) is relevant for easing symptoms related to physical discomfort in clinical situations where inflammation and resulting airway obstruction are sources of distress. Its application is applicable within clinical settings where patients experience inflammatory conditions that require supportive symptom management.

The medication is considered relevant for managing acute inflammatory diseases of the respiratory tract and ENT organs. It may be part of symptomatic management in conditions like acute bronchitis, rhinopharyngitis, and laryngitis. A relevant therapeutic domain involves addressing symptoms of bronchial spasm and airway muscle tightness, which is considered relevant in obstructive airway diseases.

“Fenspiride may assist with maintaining a sense of stability when symptoms are more noticeable, by is relevant for easing distress related to inflammatory and irritative states.”

This symptomatic support contributes to day-to-day comfort by is relevant for easing the functional strain of the airways. It is applied when symptoms become more disruptive, and may assist with maintaining functional stability, particularly when patients experience a persistent, irritating cough and excessive expectoration.

---

Quick Fact: Supports Management of Inflammation and Spasm

Eligibility Map: Official Regulatory Information

The eligibility profile for Фенспирид (Fenspiride) is largely determined by regulatory actions related to serious safety concerns.

Category	Official Regulatory Statement
Populations for whom use is allowed	None in jurisdictions where marketing authorization has been revoked (e.g., European Union) due to an unfavorable risk-benefit assessment [EMA Withdrawal].
Populations for whom use is contraindicated	Patients with a history or risk of serious heart rhythm problems, including QT prolongation or Torsades de Pointes [EMA Suspension].
	Individuals with a known hypersensitivity to the active substance or excipients [Source 2.4].
Age-related eligibility rules	Children under 2 years of age are contraindicated [Source 2.4]. Use in adults and older children is affected by the revocation in key markets.
Pregnancy and lactation eligibility	Use is not recommended during either pregnancy or breastfeeding because safety data in these specific populations has not been fully established [Source 2.5].

Official regulatory documents define non-eligibility by establishing absolute contraindications tied to cardiac risk and hypersensitivity. The overall eligibility structure reflects a major regulatory constraint, resulting in the prohibition of the medicine's market presence and prescription in affected territories.

The official regulatory profile for Fenspiride establishes specific interaction constraints that must be observed during co-administration with other substances. A primary constraint involves the risk of cardiac toxicity resulting from an additive pharmacodynamic interaction. Co-administration with other medicinal products known to prolong the QTc interval is strictly contraindicated, based on the established potential for serious ventricular arrhythmias, including Torsades de pointes. This restriction is further noted in populations with predisposing factors for QTc changes, such as documented hypokaliemia.

A separate, documented interaction occurs with Central Nervous System (CNS) depressants, which include categories such as sedative drugs, certain antihistamines, and opioid analgesics. Co-administration with these agents may cause a potentiation of sedative effects, a result formally noted in regulatory documents. Related to this is the restriction on the consumption of alcohol (ethanol), which is documented to exacerbate the central sedative effects of the medicine. The interaction structure also notes potential pharmacokinetic interactions concerning CYP enzyme inducers or inhibitors, substances that may affect the drug's metabolism, leading to an officially described alteration in systemic exposure.

Фенспирид's action is rooted in a multitarget pharmacodynamic mechanism that influences the physiological components of inflammation and smooth muscle tone. This profile is defined by two distinct but complementary molecular domains.

Antagonism of Histamine and alpha1-Adrenergic Receptors

The molecule acts as a direct antagonist against surface receptors, primarily the Histamine H1 receptor and alpha1-Adrenergic receptors. This blockade suppresses the signals that typically trigger bronchial smooth muscle contraction and increase microvascular permeability. This molecular consequence results in decreased smooth muscle contraction and a reduction of microvascular fluid extravasation within the tissue.

Inhibition of Phosphodiesterase ( PDE) Enzymes

Фенспирид is an inhibitor of several Phosphodiesterase enzymes, notably PDE4. By slowing the breakdown of the secondary messenger cAMP within immune cells, this mechanism decreases the synthesis and release of key pro-inflammatory mediators such as leukotrienes and prostaglandins. The resulting elevation of cAMP in smooth muscle cells also promotes their relaxation, linking the anti-inflammatory effect with a decrease in muscle tone.

The official usage pattern for Fenspiride is fundamentally defined by its regulatory status. Following a review, the revocation of marketing authorizations for all fenspiride-containing medicines was recommended. Consequently, the definitive official instruction is that the medicine should no longer be prescribed, and patients are advised to stop taking it. This directive establishes the current, authoritative use principle.

Prior to the regulatory withdrawal, the administration of Fenspiride adhered to specific prescribing information. The medication was officially authorized only via the oral route, available in both tablets (e.g., 80 mg strengths) and a liquid syrup formulation (e.g., 2 mg/mL). The standard historical dosing regimen for adults typically called for a total daily dose between 160 mg and 240 mg, administered in divided doses throughout the day.

Procedural guidelines specified that the dose must be taken before meals. For pediatric patients, administration principles for children over two years of age were based on body weight, using the syrup form at a rate of approximately 4 mg per kilogram of body weight daily. While these procedures historically defined the method of administration, the current regulatory instruction to cease use is the overriding condition for the medicine.

Research evidence / Overview of studies for Фенспирид

Evidence for Symptomatic Relief in Acute Respiratory Inflammation

Фенспирид was evaluated in contexts that explored symptom patterns related to acute inflammatory respiratory tract diseases, such as acute bronchitis and rhinopharyngitis. These are conditions characterized by fluctuating or episodic manifestations like cough, sputum production, and breathing difficulty.

Studies focused on adults and separate cohorts of children (aged 2 years and older). Researchers monitored outcomes related to physical discomfort, primarily measuring changes in clinical symptom severity scores over short-term treatment intervals. Studies provided measurements of how patient-reported outcomes describing perceived discomfort changed. However, subsequent regulatory reviews have indicated that the findings were mixed across various studies, suggesting that the evidence quality varies across studies and may be limited by methodological inconsistencies.

---

Evidence for Supportive Therapy in Chronic Airway Diseases

Фенспирид was studied for its use as a supportive treatment in conditions marked by functional limitations, such as Chronic Obstructive Pulmonary Disease (COPD). Research included RCTs and observational studies focused on adults with mild to moderate COPD.

Studies monitored outcomes related to systemic or functional imbalance, examining changes in objective lung function parameters (like FEV1) and inflammatory biomarker levels. The overall evidence that was evaluated in regulatory assessments is drawn from trials where sample sizes were modest.

---

What Is Still Uncertain About Fenspiride's Clinical Evidence

The certainty surrounding the overall clinical picture of Фенспирид remains low due to several factors. Most importantly, the evidence is limited by a definitive regulatory conclusion in some major international jurisdictions (such as the European Union). This was based on the finding that the serious findings (a potential for serious heart rhythm changes) outweighed the documented symptomatic efficacy reported in the clinical studies for acute and chronic respiratory conditions.

Common questions about Фенспирид (FAQ)

---

Q: Is Фенспирид an antibiotic?

No, official regulatory classifications describe Фенспирид as a bronchodilator and a specific type of non-steroidal anti-inflammatory drug (NSAID). Its recorded use is to address inflammatory components of airway diseases, and it is not classified as an antibiotic used to kill bacteria.

---

Q: Is Фенспирид the same as a typical cough suppressant?

The mechanism of action for Фенспирид is described as dual, combining anti-inflammatory effects with the relaxation of airway muscles (bronchodilation). This profile is generally considered distinct from single-mechanism medicines classified only as cough suppressants (antitussives), which are primarily used to stop the cough reflex.

---

Q: What is the difference between Фенспирид and other anti-inflammatory drugs?

Official information highlights that Фенспирид has a dual physiological action. In addition to targeting inflammation, it also acts to promote airway muscle relaxation, which is a differentiating feature when compared to some other anti-inflammatory drugs.

---

Q: How long does the effect of Фенспирид last?

Pharmacokinetic data indicates that the time required for half the substance to be eliminated from the body, known as the elimination half-life, is approximately 14–16 hours.

---

Q: Is it normal to feel sleepy after taking Фенспирид?

Yes, regulatory documents list somnolence, or drowsiness/sleepiness, as a common adverse reaction associated with the use of the medicine. This is a potential effect noted in the official safety profile.

---

Q: Can Фенспирид be taken with pain relievers like paracetamol?

Regulatory documents caution against combining Фенспирид with medicines known to prolong the QTc interval or with Central Nervous System (CNS) depressants. Paracetamol is not explicitly listed as a contraindication, but patients are generally advised to discuss all co-administered medicines with a healthcare professional.

---

Q: What information should I know about Фенспирид and driving?

Due to the potential for common side effects such as dizziness and somnolence (drowsiness), regulatory warnings indicate that caution is advised when performing tasks that require concentration, such as driving or operating machinery.

---

Q: Does Фенспирид affect blood pressure?

Фенспирид acts as an antagonist against alpha1-Adrenergic receptors, which are known to influence blood vessel tone. Observations, particularly in overdose situations, have described the potential for blood pressure changes, such as orthostatic hypotension (low blood pressure when standing).

---

Q: Is there a risk of dependence or addiction with Фенспирид?

Фенспирид is not classified as a controlled substance, and official regulatory warnings related to its use primarily focus on serious cardiac risks and hypersensitivity. Warnings regarding drug dependence or addiction are not typically included in the official product information.

---

Q: What happens if a dose of Фенспирид is missed?

General regulatory guidelines on administration typically state that if a dose is missed, individuals should resume the regimen with the next scheduled dose. Compensation for a forgotten dose with a double dose is usually not recommended.

---

Q: Is it possible to take too much Фенспирид?

Yes, official regulatory documents include a section on overdose, listing potential symptoms like excitement, a rapid heart rate (tachycardia), or drowsiness. Official documents advise that individuals should seek immediate medical assistance in the event of suspected accidental or intentional overdose.

---

Q: Can older adults use Фенспирид safely?

Official regulatory warnings emphasize the risk of serious heart rhythm problems, known as QT prolongation. Although there is no specific blanket contraindication based on age alone (other than children under 2), this cardiac risk may be a particular consideration for older adults.

---

Q: Is Фенспирид available over the counter?

No, in most international jurisdictions where the medicine was or is marketed, Фенспирид is legally classified as a prescription-only medicine (POM) and requires authorization from a healthcare professional.

---

Q: Has Фенспирид been banned anywhere recently?

Yes, following a safety review, the European Medicines Agency (EMA) recommended the revocation of marketing authorizations for all fenspiride-containing medicines across the European Union. This regulatory action resulted in the medicine no longer being prescribed or available in those territories.

---

Q: Does Фенспирид help with asthma?

The medicine has historically been indicated or studied for use in the maintenance treatment of respiratory diseases, which includes asthma, alongside inflammatory conditions of the Ear, Nose, and Throat (ENT) organs and lower respiratory tract.

---

Q: Are there any food restrictions while taking Фенспирид?

Historical administration instructions recommend taking the dose before meals. Although specific food restrictions are not typically listed in the interaction documents, the consumption of alcohol is explicitly prohibited due to the risk of exacerbating sedative effects.

---

Q: Does the evidence support the use of Фенспирид for all types of respiratory infections?

Official therapeutic indications for the medicine are restricted to specific acute and chronic inflammatory diseases of the ENT organs and the respiratory tract. This suggests it is not generally indicated or evaluated for all types of respiratory infections.

---

Q: What should I do if I have a severe allergic reaction to Фенспирид?

Official warnings state that the onset of a serious allergic reaction, such as swelling, rash, or breathing difficulties, requires immediate medical attention. Hypersensitivity to the substance is noted as a contraindication in regulatory documents.

---

Q: Does Фенспирид interact with diabetes medications?

While direct drug-to-drug interactions with specific diabetes medicines may not be broadly listed, the syrup formulation of Фенспирид contains sucrose (sugar). This sugar content is noted in official product information as a factor relevant for individuals with diabetes mellitus.

---

Q: Is Фенспирид considered a standard treatment for ear infections?

Official regulatory documents have historically included otitis (ear infections) under the list of inflammatory diseases of the ENT organs for which Фенспирид was indicated as symptomatic treatment, often alongside other prescribed therapies.

---

Q: How does Фенспирид differ from mucolytics?

Фенспирид’s reported primary actions are anti-inflammatory and bronchodilating (relaxing airway muscles). This mechanism is pharmacologically distinct from mucolytics, which are a class of agents that primarily work to break down and thin the consistency of mucus.

---

Q: Are there specific symptoms that require immediate medical attention while on Фенспирид?

Regulatory warnings indicate that symptoms such as palpitations, abnormal heart rhythms, or signs of a severe allergic reaction (hypersensitivity) necessitate immediate medical attention. These symptoms are related to serious risks identified in the official safety profile.

---

Q: Can Фенспирид be taken on an empty stomach?

Historical administration instructions specified that the dose must be taken before meals. This guidance was intended to optimize the medicine’s absorption and tolerability.

---

Q: What is the proper way to discontinue taking Фенспирид?

Following the negative risk-benefit assessment, the definitive instruction from regulatory authorities in some major markets (like the European Union) is that patients should stop taking the medicine entirely. Any unused portions should be returned to a pharmacist for proper disposal.

---

Q: Does Фенспирид help reduce mucus production?

Studies have examined outcomes related to sputum (mucus) quality and quantity in patients treated with the medicine, indicating this is a documented area of research related to the treatment of inflammatory respiratory conditions.

Official Storage and Disposal Requirements

Storage and disposal instructions for Fenspiride (Фенспирид) are strictly defined by regulatory labeling to ensure product stability and environmental safety.

Requirement	Official Regulatory Statement
Temperature	Do not store above 25 C. Do not refrigerate or freeze.
Packaging	Keep the medicine in its original light-protective container (brown bottle).
In-Use Stability	Discard the product 6 months after the bottle is first opened, regardless of the printed expiration date.
Child Safety	Keep the medicine out of the sight and reach of children.
Disposal	Return any unused or expired medicine to a pharmacy for proper disposal.

Regulatory mandates emphasize that the product must be stored within the specified temperature range to maintain effectiveness. Proper disposal by returning the product to a collection point is necessary to prevent environmental contamination, as the substance must not be discharged into drains or household waste.